You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Oncol., 20 August 2025

Sec. Head and Neck Cancer

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1637309

Correction: Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy

  • Radiation Oncology Center, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China

Article metrics

View details

632

Views

198

Downloads

In the published article, there was an error in the legend for Figure 3 as published. Risk classification should be low, medium and high risk rather than no risk, low risk and high risk. The corrected legend appears below.

Figure 3

Two Kaplan-Meier survival plots compare low, medium, and high-risk groups. Chart A shows overall survival; the low-risk group has the highest survival rate, followed by medium and high-risk (P=0.0008). Chart B shows progression-free survival with similar trends (P=0.0007). Time is measured in months.

Kaplan-Meier curves of overall survival (A) and progression-free survival (B) of patients in different risk groups.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

peripheral blood monocyte count, GTVnx, nasopharyngeal carcinoma, radiotherapy, overall survival

Citation

Yang L-N, Song Y-R, Zhang H, Tu H-L, Lu M-Y, Liu D-Q, Sui J-D, Li D, Xie Y and Wang Y (2025) Correction: Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy. Front. Oncol. 15:1637309. doi: 10.3389/fonc.2025.1637309

Received

29 May 2025

Accepted

08 August 2025

Published

20 August 2025

Volume

15 - 2025

Edited and reviewed by

Jan Baptist Vermorken, University of Antwerp, Belgium

Updates

Copyright

*Correspondence: Dan Li, ; Yue Xie, ; Ying Wang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics